In a recent New York Times article, Harvard economist Sendhil Mullainathan articulates strong support for clinically nuanced,
value-based insurance design (V-BID) programs. Mullainathan highlights the well-documented problem of cost-related medication
non-adherence and recommends that high-value drugs such as those that treat heart disease and diabetes be provided at no cost to
the populations that need them.
The concept of 'clinical nuance' was developed at the University of Michigan Center for Value-Based Insurance Design. The basic tenets of clinical nuance are: 1) medical services and providers differ in the benefit provided; and 2) the clinical benefit of the service depends on the person using it, as well as where and by whom the service is provided. Unlike "one-size-fits-all" plan designs that set a single co-payment for all clinician visits, diagnostic tests and drugs, V-BID programs base cost-sharing on the clinical value of the service--not the cost. Published evidence concludes that clinically nuanced cost-sharing can improve care quality and lower health care expenditures while fostering consumer engagement. V-BID programs targeting evidence-based preventive care, clinician visits, diagnostic tests, drugs, and procedures have been implemented by hundreds of private and public organizations nationally.
For more information, please contact V-BID Center Director, A. Mark Fendrick, MD at email@example.com or 734-647-9688.
To receive the latest news and updates on V-BID, please sign up to receive our newsletter and follow us on twitter.